Sign in
WithdrawnNo phase

StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients

Key facts

Who runs it
OHSU Knight Cancer Institute
Where
Portland, United StatesSee the site
Trial code
Status
Withdrawn
Started
1 Jan 2024
Ended
1 Jul 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Calendula Ointment
  • Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment
  • Polyethylene Glycol Hydrogel
  • Silicone-based Film Forming Topical Gel
  • Silver Sulfadiazine
  • Topical Hydrocortisone
Record updated
6 May 2024
Why it stopped
study staff transition

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Patients will be adult (> age of 18) patients. Both men and women and members of all races and ethnic groups will be included
  • Histologically confirmed malignancy for which standard curative measures in conjunction with radiotherapy are indicated to the following sites: whole breast/chest-wall for post-surgical radiotherapy or bilateral neck (levels one through six) for head and neck cancer
  • All head and neck cancer patients should have the left and right neck treated to the same dose when receiving bilateral neck irradiation
  • Ability to understand and the willingness to sign a written informed consent document

Who cannot take part

  • History of prior radiotherapy to involved site within 5 cm of anticipated treatment field
  • Patients receiving concurrent capecitabine
  • Presence of psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. (i.e. schizophrenia, autism, temporary housing during treatment, scheduling conflict immediately after treatment. This will need to be assessed prior to consent
  • Anticipated or actual use of other non-study topical medications or remedies in the treatment field
  • Patients receiving ultra-hypofractionated radiation to the breast
  • Clinically evident skin involvement of malignancy
  • Evidence of active cellulitis or wound infection involving anticipated treatment site
  • Thin patients with nodal involvement requiring bolus
  • Patients with significant unshaven facial or chest wall hair compromising film application
  • Eastern Cooperative Oncology Group (ECOG) performance status >= 3
  • Patient with skin grafts over treatment site(s)
  • Actual or perceived inability to reliably apply StrataXRT to the patients treatment field in the home environment
  • Vulnerable populations (pregnant women, decisionally impaired adults, and prisoners) will be excluded from the study

Where in United States

  • OHSU Knight Cancer InstitutePortland, United States

About the trial

What the trial wants to find out

This clinical trial studies the effect of StrataXRT in preventing and treating radiation dermatitis in breast cancer or head and neck cancer patients. Radiotherapy is often associated with multiple side effects. These side effects can cause patient injury and make it difficult to complete treatment. For example, radiation dermatitis or skin damage may result in severe skin peeling and skin irritation. Depending on the location of radiation, the skin damage can cause problems and be tough to heal. This trial aims to see whether StrataXRT may help to prevent dermatitis after radiation therapy.

The 2 groups in the trial

  • Arm I (StrataXRT)Treatment being tested

    Patients apply StrataXRT topically to the affected area once or twice daily starting from the first dose of radiation therapy until dermatitis has returned to grade =\< 1.

    Treatment: Silicone-based Film Forming Topical Gel

  • Arm II (standard of care)Existing treatment, for comparison

    Patients receive standard of care including calendula and/or Aquaphor applied 2-6 times daily plus hydrogel or Silvadene or topical corticosteroids applied twice daily starting from the first dose of radiation therapy until dermatitis has returned to grade =\< 1.

    Treatment: Calendula Ointment, Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment, Polyethylene Glycol Hydrogel, Silver Sulfadiazine, and Topical Hydrocortisone

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized Intra-Patient Controlled Study of StrataXRT ® Versus Current Practice to Prevent and Treat Radiation Dermatitis
Record updated
6 May 2024